Following a 10-year evolution in transcatheter valve design and refinements in procedural techniques, stroke rates during TAVR have been relatively stagnant over time (4, 5) . In addition to the occurrence of clinically-apparent stroke, several studies utilizing serial brain magnetic resonance imaging (MRI) systematically demonstrated silent new cerebral lesions in at least two-thirds of individuals undergoing TAVR (3). Although these findings may, to some extent, simply reflect the nature of TAVR in a highrisk patient substrate with extensive comorbidities, this may also reflect a fundamental limitation of contemporary TAVR techniques. Yet, the quest for TAVR to emerge as a viable alternative to SAVR in lower-risk, younger patients with severe aortic stenosis is inevitable. Therefore, minimizing peri-TAVR stroke risk to levels equivalent to or even lower than those following SAVR looms as an important challenge.
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